A nonprofit–industry partnership, led by RCSI University of Medicine and Health Sciences of Dublin and SkylineDx, aims to advance genetic testing to better guide doctors in making treatment choices for people with multiple myeloma, based on each patient’s likely response. A planned study in patients, conducted with funding from Amgen, Janssen, and Celgene, will take place at the Beaumont Hospital Dublin and run through the Blood Cancer Network Ireland — a network of scientists and hematologists promoting work…
You must be logged in to read/download the full post.
The post Planned Study Aims for Way to Personalize Multiple Myeloma Treatment appeared first on BioNewsFeeds.